Taiho Pharmaceutical vs. Natco Pharma: Dismissed With Prejudice in Oncology Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Taiho Pharmaceutical Co., Ltd. et al. v. Natco Pharma Ltd. et al. |
| Case Number | 1:22-cv-01480 |
| Court | U.S. District Court for the District of Delaware |
| Duration | Nov 2022 – Apr 2024 17 months (518 days) |
| Outcome | Dismissed With Prejudice |
| Patents at Issue | |
| Accused Products | Method for treating cancer patients with severe renal impairment (Natco’s generic development efforts) |
Case Overview
The Parties
⚖️ Plaintiff
Tokyo-headquartered oncology-focused pharmaceutical company with a strong portfolio of cancer therapies, including its U.S. subsidiary, Taiho Oncology, Inc.
🛡️ Defendant
Hyderabad, India-headquartered generics manufacturer, active in challenging branded pharmaceutical patents through ANDA filings. Its U.S. entity, Natco Pharma, Inc., serves as its domestic operational arm.
The Patent at Issue
The patent at issue, U.S. Patent No. US10456399B2 (application number US16/054073), covers a method for treating cancer patients with severe renal impairment. Method-of-treatment patents protect specific clinical use protocols rather than chemical compounds themselves, which makes them both commercially powerful and legally distinctive — their claim scope turns heavily on dosing regimens, patient subpopulations, and clinical parameters.
- • US10456399B2 — Method for treating cancer patients with severe renal impairment
Developing a generic oncology drug?
Check if your product’s treatment method might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
On April 11, 2024, the parties filed a Stipulation of Dismissal With Prejudice pursuant to Federal Rules of Civil Procedure 41(a) and 41(c). The stipulation dismissed all claims, counterclaims, and defenses asserted by both parties. Critically, each party agreed to bear its own costs and attorneys’ fees — a standard settlement posture indicating neither side extracted a fee-shifting concession.
Legal Significance
The dismissal with prejudice is legally significant in one key respect: Taiho cannot reassert the same claims against Natco on the same patent and accused product. This provides Natco with permanent protection from re-litigation on those specific grounds. However, because no court ruled on patent validity, **US10456399B2 remains valid and enforceable** against other potential infringers — its legal standing is unaffected by this dismissal.
The U.S. District Court for the District of Delaware retained jurisdiction to enforce the terms of the parties’ resolution and resolve any future disputes arising from the settlement — standard language that signals a confidential underlying agreement (likely a license, consent judgment, or market entry date stipulation) governs the parties’ ongoing relationship.
Freedom to Operate (FTO) Analysis in Oncology
This case highlights critical IP risks in pharmaceutical method-of-treatment patents. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View the patent and its claim scope
- Analyze prosecution history and prior art
- Understand method-of-treatment strategy
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own oncology product or method.
- Input your drug’s treatment protocols or patient populations
- AI identifies potentially blocking method patents
- Get actionable risk assessment report
Method-of-Treatment Risk
Specific patient populations (e.g., renal impairment)
1 Patent at Issue
US10456399B2 focused on a method claim
Settlement Averts Trial
No judicial invalidation of patent
✅ Key Takeaways
Dismissal with prejudice under FRCP 41(a)/(c) bars re-litigation of identical claims but leaves the patent’s validity intact against third parties.
Search related case law →Delaware remains the dominant forum for pharmaceutical patent disputes; familiarity with its procedural norms is essential.
Explore court dockets →Method-of-treatment patents covering patient subpopulations offer durable enforcement vehicles beyond compound patent expiration.
Analyze claim scope →FTO analyses must extend to method-of-treatment patents covering dosing modifications for clinical subgroups — not just composition-of-matter claims.
Start FTO analysis for my product →Early engagement with IP counsel when developing generics targeting specialty oncology indications can reduce downstream litigation exposure.
Find IP counsel →Frequently Asked Questions
U.S. Patent No. US10456399B2, covering a method for treating cancer patients with severe renal impairment, was the sole patent asserted in this case.
The parties mutually stipulated to dismissal under FRCP 41(a) and 41(c) by agreement, with each side bearing its own fees — indicating a private resolution. No court ruling on infringement or validity was issued.
The case reinforces that method-of-treatment patents for defined patient subpopulations are viable enforcement tools, and that pharmaceutical patent disputes frequently resolve through negotiated agreements rather than trial verdicts.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Center – US10456399B2
- PACER Case Lookup – 1:22-cv-01480
- U.S. District Court for the District of Delaware
- Cornell Legal Information Institute — FRCP 41
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.